High expression of nucleoporin 133 mRNA in bone marrow CD138+ cells is a poor prognostic factor in multiple myeloma

Recent advances in plasma cell biology and molecularly-targeted therapy enable us to employ various types of drugs including immunomodulatory drugs, proteasome inhibitors, and immunotherapy. However, the optimal therapeutic strategies to introduce these drugs for heterogeneous patients with multiple...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: Ibata, Soushi, Kobune, Masayoshi, Kikuchi, Shohei, Yoshida, Masahiro, Miura, Shogo, Horiguchi, Hiroto, Murase, Kazuyuki, Iyama, Satoshi, Takada, Kohichi, Miyanishi, Koji, Kato, Junji
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2018
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5982762/
https://ncbi.nlm.nih.gov/pubmed/29861858
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25350
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires